Navigation Links
Research becomes a reality for Rett syndrome through new funding
Date:10/1/2010

on the partnership award to Dr. Amendola saying, "Our shared goals and research endeavors will benefit children affected by both CDKL5 and Rett syndrome and we are proud to partner with IRSF in co-funding this project. Finding a cure is our top priority and this is a critical step forward."

New Translational Research Awards Announced

In addition to the regular research awards, IRSF recently launched "Research to Reality" an aggressive fundraising campaign spearheaded by IRSF's HeART and ANGEL grant awards which provide funding for drug discovery, development and testing. The first HeART grant awards will provide seed funding for the following early stage drug discovery programs:

  • "Serotonin and small molecule treatment of respiratory disorders in a mouse model of Rett syndrome" John M. Bissonnette, Oregon Health & Science University
  • "Novel screening methods for quantitative, homeostatic regulation of MeCP2", Rajiv Ratan, MD, PhD, Burke Medical Research Institute, Weill Medical College of Cornell University
  • "A high throughput small molecule screening platform for potential Rett syndrome MBD mutation therapeutics", Yi Eve Sun, MD, PhD, University of California, Los Angeles
  • "Evaluating carbonic anhydrase inhibitors as potential treatments for Rett syndrome", Liang Zhang, MD, PhD, University Health Network, Toronto Western Hospital

Earlier this year, IRSF announced funding of the first ANGEL award totaling $446,000 to support a program testing new treatments for breathing dysfunction in Rett syndrome to David Katz PhD, Case Western Reserve University.

Dr. Antony Horton IRSF Chief Scientific Officer commented, "Together these new basic and translational research awards are beginning to fulfill the promise of our 'Research to Reality' campaign which seeks to move discoveries out of the lab and translate them into new medicines for Rett syndrome." Dr. Horton added "In addition to this announce
'/>"/>

Contact: Stephen Bajardi
sbajardi@rettsyndrome.org
International Rett Syndrome Foundation
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. OU researchers selected by Navy
2. RIT receives federal grant to construct new sustainability research facility
3. Iowa State University researcher examines mosquito gene for new disease response
4. NIH awards Rutgers $47.5 million to advance groundbreaking research on protein structures
5. NIH Transformative Research Project Awards hasten innovation
6. Cold Spring Harbor Laboratory neuroscientist awarded Transformative NIH research grant
7. Scripps Research scientists win $65 million in new grants to reveal form and function of proteins
8. OHSU Toxicology Research Center issues public alert on popular hair salon treatment
9. Renewable energy research center to be established in southern Israel
10. $1.5M grant funds research aimed at reducing strokes in children with sickle cell disease
11. Research examines vicious cycle of overeating and obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Hole Research Center are analyzing the surprising results of the ... rainforest. , From January 2000 to July 2004, rainfall was ... of the Tapajós National Forest, in Brazil. A total of ... by 6' clear plastic panels suspended 3 to 12 feet ...
... Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska ... a strategic alliance designed to improve healthcare by ... tools for better diagnosis, prognosis, and treatment. , ... genetic analyses and measurement of gene expression in ...
... have discovered an important chemical in the brain's ... symptoms of opioid drugs like morphine and heroin. ... chemical--called a transporter--could relieve some of the early ... shaking, and jumpiness. Such drugs could become part ...
Cached Biology News:World's largest rainforest drying experiment completes first phase 2World's largest rainforest drying experiment completes first phase 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3Key Trigger Of Opioid Withdrawal Symptoms Found 2
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Argentina Biomedical Sensors Market - Growth, Trends & ... The Argentina Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:8/31/2015)... people with Down syndrome, news from Elixirgen, LLC ... in the Science + Technology Park at Johns Hopkins, ... for people with Down syndrome and other chromosome disorders in ... Edwards syndrome aneuploidies in human cell cultures, " published ... to develop this technology into a treatment for the ...
(Date:8/31/2015)... Calif. and SHANGHAI ... a privately-held biopharmaceutical company developing next-generation antibiotics, today ... 2 clinical study for its lead drug candidate ... to treat drug-resistant bacteria such as MRSA and ... and better tolerated therapeutic option than currently available ...
(Date:8/31/2015)... ... 31, 2015 , ... Regulatory agencies have acknowledged impurities especially ... process. Thus, innovator companies must understand what will be needed in the drug ... been hosting multiple educational panels and seminars for experts to share advice concerning ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... Brain Metastases, PALO ALTO, Calif., Sept. 2 ... radiosurgery treatments for,multiple brain metastases using new RapidArc ... ). The MIMA Cancer Center in Melbourne,Florida and ... able to treat brain metastases more quickly and ...
... BMRN ) today announced that Jean-Jacques,Bienaime, Chief Executive ... 3rd Annual Citi Biotech Day in New York City ... Interested parties may access a live audio webcast of ... website, http://www.BMRN.com .,A replay of the call will ...
... development milestone payment to InterMune - ... to lead ITMN-191 program in Phase 2 -, BRISBANE, ... announced that InterMune has earned a $15 million,development milestone under ... NS3 protease inhibitor compound ITMN-191,(referred to as R7227 at Roche), ...
Cached Biology Technology:Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 4BioMarin to Present at the Citi Biotech Day 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
... is a cytidine analog that has been shown ... Immunogen: Chemical / Small Molecule conjugated ... of the ddC antiserum was determined by calculating ... moles of ddC analog at the 50% intercept ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
...
... The Holten MaxiSafe 2010 Class II ... ergonomical working condition of comfort while ... efficiency and performance.,Refined operator, environment and ... both exhausted and recirculated air.,Bottom filters ...
Biology Products: